drugset / Trial / NCT00572013
Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.
Timeline
- Start
- 1998-05-12
- Primary completion
- 2001-01-01
- Completion
- 2009-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 100 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Background | carmustine | Small molecule | 300 mg/m2 | Intravenous |